Leverage Analysis Stories

SCHULMAN upswings slowly despite modest market decline

  20 hours ago at Macroaxis 
By Raphi Shpitalnik
This story will recap SCHULMAN INC. We will focus on the cause of why it is still reasonable for the firm to generate above-average margins and lots of cash flow. SCHULMAN INC current daily volatility is 1.31 percent, with a beta of -0.14 and an alpha of 0.2 over DOW. We estimate SCHULMAN INC as currently fairly valued. The real value is approaching 985.35 per share. SCHULMAN... [more]
The entity has accumulated 918.45 M in total debt with debt to equity ratio (D/E) of 4.51, indicating the entity may have difficulties to generate enough cash to satisfy its financial obligations. The firm has accumulated 918.45 M in total debt with debt to equity ratio (D/E) of 4.51, indicating the stock may have difficulties to generate enough cash to satisfy its financial obligations. SCHULMAN INC has a current ratio of 1.69, which is within standard range for the sector.
M-
  13 hours ago at Macroaxis 
By Achuva Shats
In this story, I am going to address all Microsectors -3X shareholders. We will look into why despite regular market tumult, the longer-term fundamental drivers of the fund are still sound. Microsectors -3X current daily volatility is 25.72 percent, with a beta of 0.48 and an alpha of 1.7 over DOW. The entity slowly supersedes the market. Microsectors -3X secures a last-minute Real Value of $17.33 per share. The latest price of the etf is $17.5. At this time, the etf appears to be fairly valued. Our model forecasts the value of Microsectors -3X from analyzing the etf fundamentals such as number of employees of 27, and net asset of 23.75 M as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend purchasing undervalued stocks and exiting overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
<div class='circular--portrait-small' style='font-weight: 700;background:#8B008B;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>AT</div>
  17 hours ago at Macroaxis 
By Achuva Shats
This article will break down few interesting ideas for the current Aldeyra Therapeutics investors and investors who consider a position in the company. We will inspect if investors should continue to be optimistic for the company outlook. The entity current daily volatility is 6.97 percent, with a beta of 0.15 and an alpha of 1.36 over DOW. We estimate Aldeyra Therapeutics as currently undervalued. The real value is approaching 9.18 per share. We have analyzed and interpolated thirty-one available fundamental indicators for Aldeyra Therapeutics, which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Aldeyra Therapeutics financials, including its number of shares shorted, book value per share, working capital, as well as the relationship between the cash and equivalents and number of employees . Given that Aldeyra Therapeutics has a price to earning of (4.44) X, we suggest you to validate Aldeyra Therapeutics prevailing market performance to make sure the company can sustain itself down the road. Use Aldeyra Therapeutics to enhance returns of your portfolios. The stock experiences a moderate upward volatility. Check odds of Aldeyra Therapeutics to be traded at $4.8 in 30 days.
<div class='circular--portrait-small' style='font-weight: 700;background:#006400;color: #FFE4E1;font-size:1.1em;padding-top: 10px;;'>SI</div>
  20 hours ago at Macroaxis 
By Raphi Shpitalnik
This story will recap SCHULMAN INC. We will focus on the cause of why it is still reasonable for the firm to generate above-average margins and lots of cash flow. SCHULMAN INC current daily volatility is 1.31 percent, with a beta of -0.14 and an alpha of 0.2 over DOW. We estimate SCHULMAN INC as currently fairly valued. The real value is approaching 985.35 per share. SCHULMAN INC appears to be very steady, given 1 month investment horizon. SCHULMAN INC owns Efficiency Ratio (i.e. Sharpe Ratio) of 0.21, which indicates the company had 0.21% of return per unit of volatility over the last month. Our viewpoint regarding measuring the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for SCHULMAN INC, which you can use to evaluate future volatility of the entity. Please operate SCHULMAN INC market risk adjusted performance of (1.29), downside deviation of 3.24, and risk adjusted performance of 0.2029 to confirm if our risk estimates are consistent with your expectations.
<div class='circular--portrait-small' style='font-weight: 700;background:#9CBEFD;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>NI</div>
  21 hours ago at Macroaxis 
By Vlad Skutelnik
Today's article will go over NanoViricides Inc. We will look into why albeit cyclical market disturbance, the long term basic indicators of the company are still strong. The firm current daily volatility is 9.55 percent, with a beta of -0.85 and an alpha of 0.91 over DOW. NanoViricides NEW Piotroski F Score is 3 - Frail. NanoViricides Inc is relatively risky given 1 month investment horizon. NanoViricides NEW has Sharpe Ratio of 0.11, which conveys that the firm had 0.11% of return per unit of risk over the last month. Our standpoint towards estimating the risk of a stock is to use both market data as well as company specific technical data. We were able to interpolate and analyze data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.1% are justified by taking the suggested risk. Use NanoViricides NEW mean deviation of 6.17, downside deviation of 6.41, and risk adjusted performance of 0.1727 to evaluate company specific risk that cannot be diversified away.
<div class='circular--portrait-small' style='font-weight: 700;background:#347AFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>PT</div>
  22 hours ago at Macroaxis 
By Ellen Johnson
This post, will break down some ideas directed to Powerbridge Technologies investors who consider shorting the enterprise. We will evaluate if Powerbridge Technologies shares are excessively priced going into August. The entity current daily volatility is 7.18 percent, with a beta of 0.49 and an alpha of 0.15 over DOW. The company current odds of distress is under 3 percent. Will the stock executives continue to add value? We were able to interpolate data for thirty-four available financial ratios for Powerbridge Technologies, which can be compared to its competitors. To make sure the equity is not overpriced, please check all Powerbridge Technologies financials, including its cash and equivalents, as well as the relationship between the cash flow from operations and retained earnings . Please also confirm Powerbridge Technologies number of shares shorted to check out the company can sustain itself down the road. Use Powerbridge Technologies to enhance returns of your portfolios. The stock experiences a very speculative upward sentiment. Check odds of Powerbridge Technologies to be traded at $3.56 in 30 days.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;padding-top: 10px;;'>AF</div>
  a day ago at Macroaxis 
By Raphi Shpitalnik
The entity current daily volatility is 0.86 percent, with a beta of 0.34 and an alpha of -0.59 over DOW. What is Aeon Fincl probability of distress for August 2020? What is Aeon Fincl Target Price Odds to finish over Current Price? Based on a normal probability distribution, the odds of Aeon Fincl to move above the current price in 30 days from now is about 56.37%. The Aeon Fincl Svcs probability density function shows the probability of Aeon Fincl OTC Stock to fall within a particular range of prices over 30 days. Assuming the 30 trading days horizon, Aeon Fincl has a beta of 0.3403 . This suggests as returns on the market go up, Aeon Fincl average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Aeon Fincl Svcs will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this equity is not justified. Aeon Fincl Svcs is significantly underperforming DOW.
<div class='circular--portrait-small' style='font-weight: 700;background:#4E8BFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>EC</div>
  a day ago at Macroaxis 
By Ellen Johnson
The firm current daily volatility is 12.29 percent, with a beta of 0.37 and an alpha of 0.3 over DOW. What is Emmis Communications chance of financial distress for August 2020? Emmis Communications shows a prevailing Real Value of $1.31 per share. The current price of the firm is $1.65. Based on Macroaxis valuation methodology, the firm appears to be overvalued. Our model computes the value of Emmis Communications from reviewing the firm fundamentals such as current valuation of (6.55 M), shares outstanding of 12.16 M, and profit margin of 127.13 % as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we advise buying undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF0000;color: #F5FFFA;font-size:1.1em;padding-top: 10px;;'>AL</div>
  a day ago at Macroaxis 
By Vlad Skutelnik
The firm current daily volatility is 7.27 percent, with a beta of 0.7 and an alpha of 2.11 over DOW. Altimmune follows the market closely. Altimmune shows a prevailing Real Value of $13.14 per share. The current price of the firm is $17.03. At this time, the firm appears to be overvalued. Our model approximates the value of Altimmune from analyzing the firm fundamentals such as operating margin of (454.94) %, return on equity of (44.08) %, and shares outstanding of 21.61 M as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
<div class='circular--portrait-small' style='font-weight: 700;background:#006400;color: #FFE4E1;font-size:1.1em;padding-top: 10px;;'>SP</div>
  a day ago at Macroaxis 
By Raphi Shpitalnik
This perspective will recap Simulations Plus. I will focus on the cause of why it is still reasonable for the firm to generate above-average margins and lots of cash flow. The firm current daily volatility is 4.29 percent, with a beta of -0.12 and an alpha of 0.97 over DOW. What is Simulations Plus probability of financial unrest for August 2020? Simulations Plus has a current Real Value of $45.48 per share. The regular price of the company is $61.65. At this time, the company appears to be overvalued. Our model measures the value of Simulations Plus from inspecting the company fundamentals such as return on equity of 24.54 %, shares outstanding of 17.77 M, and operating margin of 33.11 % as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend obtaining undervalued stocks and abandoning overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page